193 related articles for article (PubMed ID: 35320355)
1. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
2. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.
Chachad D; Patel LR; Recio CV; Pourebrahim R; Whitley EM; Wang W; Su X; Xu A; Lee DF; Lozano G
Cancer Res; 2023 Jul; 83(14):2297-2311. PubMed ID: 37205631
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
4. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
5. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
6. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
7. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
[TBL] [Abstract][Full Text] [Related]
8. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
9. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
10. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
[TBL] [Abstract][Full Text] [Related]
12. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
[TBL] [Abstract][Full Text] [Related]
13. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
Xiong S; Tu H; Kollareddy M; Pant V; Li Q; Zhang Y; Jackson JG; Suh YA; Elizondo-Fraire AC; Yang P; Chau G; Tashakori M; Wasylishen AR; Ju Z; Solomon H; Rotter V; Liu B; El-Naggar AK; Donehower LA; Martinez LA; Lozano G
Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11145-50. PubMed ID: 25024203
[TBL] [Abstract][Full Text] [Related]
14. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
15. Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma.
Liu DD; Kang Y
Genes Dev; 2017 Sep; 31(18):1823-1824. PubMed ID: 29051386
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
[TBL] [Abstract][Full Text] [Related]
17. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
18. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]